MIRATI THERAPEUTICS ($NASDAQ:MRTX) reported total revenue of USD 16.4 million for the third quarter of fiscal year 2023, ending on September 30 2023, which was an increase from the USD 5.4 million reported in the same period the year prior. Net income also improved, totaling at USD -161.9 million, compared to the -173.6 million reported in the previous year.
Monday marked a successful day for MIRATI THERAPEUTICS, as the company reported its third quarter fiscal year 2023 earnings results. MIRATI THERAPEUTICS’ stock opened at $56.1 and closed at $56.3, representing an increase of 0.4% from the previous closing price of 56.0. This outcome demonstrates the positive impact of the company’s innovative treatments and therapies, and positions MIRATI THERAPEUTICS as a leader in the healthcare industry. The company’s revenue growth was driven by continued strong demand for its leading drug, sitravatinib, together with increasing sales of its targeted therapies and treatments.
Moreover, MIRATI THERAPEUTICS’ efforts to expand its pipeline with new therapies has helped to further support its long-term financial performance. Overall, MIRATI THERAPEUTICS’ quarterly earnings results show that the company is well positioned to continue to provide innovative treatments and therapies for patients in need. The company’s stock price rising over 0.4% is a testament to its success in the market, and is an indication of the confidence that investors have in MIRATI THERAPEUTICS’ future prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Mirati Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Mirati Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Mirati Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Mirati Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Mirati Therapeutics Intrinsic Stock Value
GoodWhale has conducted a thorough analysis of the fundamentals of MIRATI THERAPEUTICS and our proprietary Valuation Line has determined that the fair value of MIRATI THERAPEUTICS share is around $140.0. At the current market price of $56.3, this means that MIRATI THERAPEUTICS stock is being undervalued by 59.8%. This presents an excellent opportunity to accumulate this stock at a significant discount. We believe that investors who take advantage of this situation today will be rewarded in the future as the stock catches up with its fair value. More…
Star Chart Analysis
The pharmaceutical market is a highly competitive industry with various companies vying for a share of the pie. Among these is Mirati Therapeutics Inc, which is up against Fate Therapeutics Inc, Aerovate Therapeutics Inc, and Syndax Pharmaceuticals Inc. All four companies are engaged in research and development in order to bring innovative new drugs to market. The competition is fierce, but Mirati Therapeutics Inc is confident in its ability to deliver on its promises and remain a key player in the industry.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s lead product candidate is FT516, a universal allogeneic natural killer cell cancer immunotherapy. Fate Therapeutics has a market cap of $1.93 billion as of 2022 and a return on equity of -35.11%. The company’s products are still in development and have not yet been approved by the FDA.
– Aerovate Therapeutics Inc ($NASDAQ:AVTE)
Aerovate Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of inhaled therapies to treat serious respiratory diseases. The company’s product candidate, AeroVanc, is in development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. The company’s other product candidates include AeroKine for the treatment of non-cystic fibrosis bronchiectasis (NCFB) and AeroDose for the treatment of COPD.
Aerovate Therapeutics Inc has a market cap of $442.65M as of 2022 and a Return on Equity of -19.67%.
– Syndax Pharmaceuticals Inc ($NASDAQ:SNDX)
The company’s market cap is 1.33B as of 2022, a Return on Equity of -1.94%. The company focuses on the development of drugs for the treatment of cancer and other diseases.
MIRATI THERAPEUTICS reported strong financial performance for the third quarter of FY 2023, with total revenue increasing significantly from the prior year. Net income was also improved year-over-year. For investors, these positive results suggest potential growth opportunities in the pharmaceutical company.
MIRATI THERAPEUTICS has invested in research and development for new drugs, with promising candidates in its pipeline. It also continues to develop its existing products, expanding into new markets and strengthening its foothold in the industry.Overall, MIRATI THERAPEUTICS is well-positioned to grow in the coming years and could be an attractive option for investors.